		/	0	PE	1				
FORM PTO-1449/	/A and P (Ma	4:5	JUN	2 7 200	5 8	PLICATION NO.:	10/616,409	ATTY. DOCKET NO.:	I0248.70024US00
	·	/3	3 .	DF.a		ILING DATE:	July 9, 2003	CONFIRMATION NO.:	9289
INFORMA STATEMI	ENT BY A	APPI	LICA	NI	A	PPLICANT:	Adams et al.	-	
Sheet	1	of		2	- 0	ROUP ART UNIT:	1645	EXAMINER:	Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's	Çite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication or of issue of Cited Document MM-DD-YYYY	
	No.	Number	Kind Code	Document Document		
		2003/0130199	Al	von Hoersten et al.	07-10-2003	
<u>'</u>						
		<u> </u>				
		<u> </u>				
					·	

FOREIGN PATENT DOCUMENTS

Cite	For	eign Patent Docu	ment	Name of Patentee or Applicant of Cited	Date of	Translation	
No.	Office/ Country	Number	Kind Code	Document (not necessary)	Cited Document MM-DD-YYYY	(Y/N)	
	WO	03/002595	A2	Probiodrug AG et al.	01-09-2003		٩
	\						\dagger
]
					 	<u> </u>	┨
			 	· · · · · · · · · · · · · · · · · · ·			1
]
			 			·	+
	Cite No.	No. Office/ Country	No. Office/ Country Number	No. Office/ Country Number Kind Code	Cite No. Office/ Country Number Kind Code (not necessary)	Cite No. Office/ Country Number Kind Code None (not necessary) Name of Patentee of Applicant of Cited Document (not necessary) Publication of Cited Document MM-DD-YYYY	Cite No. Office/ Country Number Code Name of Patentee of Applicant of Cited Document (not necessary) Publication of Cited Document (Y/N) Name of Patentee of Applicant of Cited Document (Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
4		Press Release, Point Therapeutics, "Point Therapeutics Announces Positive Results in Phase 2: Metastatic Melanoma Program," May 14, 2005, 3 pages.	
SF		Press Release, Point Therapeutics, "Point Therapeutics Presents Positive Results in Phase 2: Talabostat Non-Small Cell Lung Cancer Study," May 17, 2005, 3 pages.	
4		ADAMS et al., "Enhanced Anti-Tumor Activity of Dipeptidyl Peptidase Inhibitor PT-100 in Combination with Chemotherapy in Mice," American Association of Cancer Research (AACR) Annual Meeting, Orlando, Florida, March 27-31, 2004, Poster 3820.	2
		CUNNINGHAM et al., "Phase 2 Study of Talabostat and Cisplatin in Stage IV Melanoma," American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Plorida, May 14, 2005, Abstract 7563.	
		CUNNINGHAM et al., "Phase 2 Trial of Talabostat and Docetaxel in Patients with Stage IIIB/IV NSCLC," American Society of Clinical Oncology (ASCO) Annual Meeting, May 17, 2005, Poster 7120.	

909308.1

Bronden Futte 10/11/2015

APPLICATION NO.: 10/616,409 ATTY. DOCKET NO.: 10248.70024US00 FORM PTO-1449/A and B (Modified) FILING DATE: July 9, 2003 CONFIRMATION NO.: 9289 INFORMATION DISCLOSURE APPLICANT: Adams et al. STATEMENT BY APPLICANT **GROUP ART UNIT: 1645 EXAMINER:** Not Yet Assigned 2 of 2 Sheet

NEMUNAITIS et al., "A Phase 1 Trial of Talabostat (PT-100) in Patients Receiving	
Myelosuppressive Chemotherapy," American Society of Clinical Oncology (ASCO) Annual	
Meeting, New Orleans, Louisiana, June 5-8, 2004, Poster 2572.	
REDMAN et al., "Phase 2 Trial of Talabostat in Stage IV Melanoma," American Society of Clinical	[]
Oncology (ASCO) Annual Meeting, Orlando, Florida, May 14, 2005, Abstract 7570.	

EXAMINER:	DATE CONSIDERED:
Brunder Gulder	12/11/2005

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

			OIPE				
FORM PTO)-1449/A and B (M		-MAY 0 2 2005	APPLICATION NO.:	10/616,409	ATTY. DOCKET NO.:	10248.70024US00
		ધ	А	FILING DATE:	July 9, 2003	CONFIRMATION NO.:	9289
STAT	EMENT BY	API	LOSURE C PLICANT	APPLICANT:	Adams et al.		
Sheet	1	of	4	GROUP ART UNIT:	1645	EXAMINER:	Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Docum	ment	Name of Patentee or Applicant of Cited	Date of Publication or of issue
Initials	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY
10	Al	4,499,082		Shenvi et al.	02-12-1985
1	A2	4,935,493		Bachovchin et al.	06-19-1990
	A3	5,288,707		Metternich	02-22-1994
	A4	5,296,604		Hanko et al.	03-22-1994
	A5	5,384,410		Kettner et al.	01-24-1995
	A6	5,444,049		de Nanteuil et al.	08-22-1995
	A7	5,462,928		Bachovchin et al.	10-31-1995
	A8	5,527,923		Klingler et al.	06-18-1996
	A9	5,543,396		Powers et al.	08-06-1996
	A10	5,587,299		Rettig et al.	12-24-1996
	All	5,767,242		Zimmermann et al.	06-16-1998
	A12	5,965,373		Zimmermann et al.	10-12-1999
	A13	5,965,532		Bachovchin	10-12-1999
	A14	6,040,145		Huber et al.	03-21-2000
	A15	6,090,786		Augustyns et al.	07-18-2000
	A16	6,100,234		Huber et al.	08-08-2000
	A17	6,258,597	Bl	Bachovchin et al.	07-10-2001
	A18	6,300,314	BI	Wallner et al.	10-09-2001
	A19	6,355,614	B1	Wallner	03-12-2002
	A20	6,503,882	B2	Huber et al.	01-07-2003
	A21	6,692,753	B2	Huber et al.	02-17-2004
	A22	6,703,238	B2	Bachovchin et al.	03-09-2004
	A23	6,770,628	B2	Wallner et al.	08-03-2004
	A24	6,825,169	B1	Bachovchin et al.	11-30-2004
	A25	6,846,910	B2	Zimmermann et al.	01-25-2005
	A26	6,875,737	B1	Bachovchin	04-05-2005
	A27	2003-0158114	A1	Wallner et al.	08-21-2003
	A28	2003-0212044	A1	Huber et al.	11-13-2003
6	A29	2004-0077601	Al	Adams et al.	04-22-2004
	A30	2004-0152192	Al	Bachovchin et al.	08-05-2004
NE	A31	2005-0037976	Al	Wallner et al.	02-17-2005

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	For	eign Patent Docun	nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials	No.	Office/ Country	Number	Kind Code	Document (not necessary)	Cited Document MM-DD-YYYY	(Y/N)
Br	B1	EP	0 371 467	A2	Hoechst Aktiengesellschaft	06-06-1990	Y - Abst.
BF	B2	EP	0 615 978	Al	Adir et Compagnie	09-21-1994	Y – Abst.
be	В3	EP	0 688 788	Al	Adir et Compagnie	06-22-1994	Y – Abst.

Brar

Bronder Will

W/U/rw

FORM PTO)-1449/A and B (M	lodified	n	APPLICATION NO.:	10/616,409	ATTY. DOCKET NO.:	I0248.70024US00
	RMATION D		•	FILING DATE:	July 9, 2003	CONFIRMATION NO.:	9289
	EMENT BY			APPLICANT:	Adams et al.		
,				GROUP ART UNIT:	1645	EXAMINER:	Not Yet Assigned
Sheet	2	of	4	GROOF ART UNIT.	1045	EAAWIINEK:	Hot Tet Assigned

Examiner's	Cite	For	eign Patent Docum	ent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation	
Initials	No.	Office/ Country	Number	Kind Code	Document (not necessary)	Cited Document MM-DD-YYYY	(Y/N)	
. 61	B4	wo	89/03223	A1	Bachovchin et al.	04-20-1989		
H	B5	wo	91/16339	Al	New England Medical Center Hospitals, Inc.	10-31-1991		
· W	B6	wo	91/17767	A 1	New England Medical Center Hospitals, Inc.	11-28-1991		R
br	B7	wo	92/12140	A1	Georgia Tech Research Corporation	07-23-1992		1
4	В8	wo	93/08259	A2	New England Medical Center Hospitals, Inc.	04-29-1993		
b (B9	wo	93/10127	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	05-27-1993	·	
M	B10	wo	93/16102	A1	Dana-Farber Cancer Institute	08-19-1993		
PK	B11	wo	94/03055	A1	The Government of the United States of America	02-17-1994] {
9/4	B12	wo	94/09132	A1	Dana-Farber Cancer Institute	04-28-1994] :
HY	B13	wo	95/11689	A1	Trustees of Tufts College	05-04-1995] A
BF	B14	wo	95/15309	A1	Ferring B.V.	06-08-1995]
en e	B15	WO	98/00439	A2	Trustees of Tufts College	01-08-1998		
by	B16	wo	98/50046	A1	Trustees of Tufts College	11-12-1998	•	
th.	B17	wo	98/50066	Al	Trustees of Tufts College	11-12-1998		1
87	B18	WO	99/16864	A1	Point Therapeutics, Inc.	04-08-1999		1
174	B19	WO	99/56753	Al	Point Therapeutics, Inc.	11-11-1999		1
11	B20	WO	99/62914	A1	Point Therapeutics, Inc.	12-09-1999] *
1/4	B21	wo	00/10549	A1	Point Therapeutics, Inc.	03-02-2000		7,
191	B22	wo	00/71135	A1	Point Therapeutics, Inc.	11-30-2000]*,
62	B23	WO	2004/004658	A2	Point Therapeutics, Inc.	01-15-2004		1
61/		wo	2004/004661	A2	Point Therapeutics, Inc.	01-15-2004		$_{y}$

		OTHER ART — NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
bl	C1	BAKER et al., Hydroxamates and aliphatic boronic acids: marker inhibitors for aminopeptidase. Biochemistry. 1983 Apr 26;22(9):2098-103.	
hy	C2	BORLOO et al., Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors. Verh K Acad Geneeskd Belg. 1994;56(1):57-88.	
J.	C3	HEGEN et al., The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol. 1990 Apr 15;144(8):2908-14. Abstract Only.	
h/	C4	JIANG et al., Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res Virol. 1997 Jul-Aug;148(4):255-66.	
PA,	C5	KELLY et al., Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J Am Chem Soc. 1993;115:12637-8.	
Ph	C6	KELLY et al., The efficient synthesis and simple resolution of a proline boronate ester suitable for enzyme inhibition studies. Tetrahedron. 1993;49:1009-16.	

891580.1

Berlitta

10/11/100

7. ARDS ARDS Tank

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE				APPLICATION NO.:	10/616,409	ATTY. DOCKET NO.:	I0248.70024US00
				FILING DATE:	July 9, 2003	CONFIRMATION NO.: 9289	
STATEMENT BY APPLICANT			APPLICANT:	Adams et al.			
		GROUP ART UNIT:	1645	EXAMINER:	Not Yet Assigned		
Sheet	3	of	4	CROOL ART CHIT.	1045	D/GWIIVEK.	————————

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)		
. 4/	C7	KETTNER et al., Kinetic properties of the binding of alpha-lytic protease to peptide boronic acids. Biochemistry. 1988 Oct 4;27(20):7682-8.			
. 91	C8	KETTNER et al., Peptide boronic acid inhibitors of trypsin-like proteases, their preparation and use as anticoagulants and inflammation inhibitors. Chemical Abstracts. 1990;112:80. Abstract number 91790c.			
br	C9	KINDER et al., Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Invasion Metastasis. 1992;12(5-6):309-19.			
b18	C10	KINDER et al., Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine. J Med Chem. 1990 Feb;33(2):819-23.			
hr	Cll	KINDER et al., Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase. J Med Chem. 1985 Dec;28(12):1917-25.			brack
hr	C12	KUBOTA et al., Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol. 1992 Aug;89(2):192-7.],
h/	C13	KUBOTA et al., Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol. 1994 May;96(2):292-6.			
ble.	C14	REINHOLD et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett. 1997 Jun;58(1):29-35.			
but	C15	SCANLAN et al., Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61.			
416	C16	SCHARPE et al., Purified and cell-bound CD26: enzymatic inhibition, antibody binding profile, and expression on T cells in relation to other surface markers. Verh K Acad Geneeskd Belg. 1994;56(6):537-59.			
bK	C17	SCHON et al., Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe Seyler. 1991 May;372(5):305-11.			
61	C18	SCHON et al., The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta. 1985;44(2):K9-15. Abstract Only.			
Bet	C19	SCHON et al., Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta. 1986;45(11-12):1523-8. Abstract Only.			
N.P	C20	SCHON et al., The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol. 1987 Dec;17(12):1821-6. Abstract Only.			
510	C21	SNOW et al., Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond. J Am Chem Soc. 1994;116:10860-9.			
5K	C22	SUBRAMANYAM et al., Chapter 9: CD26, a T-cell accessory molecule induction of antigen- specific immune-sppression by inactivations of CD26: A clue to the AIDS paradox? in Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response, edited by Bernhard Fleischer. 1995: R.G. Landes Company, p155-62.			
815	C23	TANAKA et al., Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481-6. Erratum in: J Immunol. 1993 Mar 1;150(5):2090.			
N/ SE	C24	TANAKA et al., The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4586-90. Abstract Only.			
br	C25	THOMPSON et al., Chapter 19: Peptide aldehydes: potent inhibitors of serine and cysteine proteases. in Methods in Enyzmology, Volume 46. Colowick et al., eds. p220-5.			

Barden Lotty

rolulaes

FORM PTO-1449/A and B (Modified) . INFORMATION DISCLOSURE . STATEMENT BY APPLICANT			APPLICATION NO.:	10/616,409	ATTY. DOCKET NO.	: 10248.70024US00	
			FILING DATE:	July 9, 2003	CONFIRMATION NO).: 9289	
			APPLICANT:	Adams et al.			
Sheet	4	of	4	GROUP ART UNIT:	1645	EXAMINER:	Not Yet Assigned
Sheet	4	01	4				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
M	C26	WELCH et al., Fluoroolefin containing dipeptide isosteres as inhibitors of dipeptidyl peptidase IV(CD26). Tetrahedron. 1996 January 1;52(1):291-304.		
130	C27	WESLEY et al., A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999 Aug 2;190(3):311-22.		
· Bill	C28	WOOD et al., Tetrapeptide inhibitors of the IgA1 proteinases from type I Neisseria gonorrhoeae. J Med Chem. 1989 Oct;32(10):2407-11.		
W	C29	YOSHIMOTO et al., Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J Biochem (Tokyo). 1985 Oct;98(4):975-9.		

EXAMINER:	DATE CONSIDERED:
L. D. AT HILL	101.10.0
Jordan Woll	Will was

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]